Sodium Bicarbonate Supplementation and Urinary TGF-

TGF-beta acidosis albumins ammonium compounds bicarbonate carbon dioxide chronic kidney disease chronic renal insufficiency creatinine diabetes mellitus diabetic nephropathies fibronectins hepatitis A virus cellular receptor 1 human FN1 protein human HAVCR1 protein human LCN2 protein humans kidney function tests lipocalin sodium bicarbonate transforming growth factors veterans

Journal

Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570

Informations de publication

Date de publication:
07 02 2020
Historique:
received: 06 06 2019
accepted: 10 12 2019
pubmed: 25 1 2020
medline: 1 6 2021
entrez: 25 1 2020
Statut: ppublish

Résumé

In early-phase studies of individuals with hypertensive CKD and normal serum total CO We conducted a randomized, double-blinded, placebo-controlled study in 74 United States veterans with type 1 or 2 diabetes mellitus, eGFR of 15-89 ml/min per 1.73 m Key baseline characteristics were age 72±8 years, eGFR of 51±18 ml/min per 1.73 m In nonacidotic diabetic kidney disease, sodium bicarbonate did not significantly reduce urinary TGF-

Sections du résumé

BACKGROUND AND OBJECTIVES
In early-phase studies of individuals with hypertensive CKD and normal serum total CO
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS
We conducted a randomized, double-blinded, placebo-controlled study in 74 United States veterans with type 1 or 2 diabetes mellitus, eGFR of 15-89 ml/min per 1.73 m
RESULTS
Key baseline characteristics were age 72±8 years, eGFR of 51±18 ml/min per 1.73 m
CONCLUSIONS
In nonacidotic diabetic kidney disease, sodium bicarbonate did not significantly reduce urinary TGF-

Identifiants

pubmed: 31974286
pii: 01277230-202002000-00009
doi: 10.2215/CJN.06600619
pmc: PMC7015087
doi:

Substances chimiques

Biomarkers 0
Fibronectins 0
HAVCR1 protein, human 0
Hepatitis A Virus Cellular Receptor 1 0
LCN2 protein, human 0
Lipocalin-2 0
TGFB1 protein, human 0
Transforming Growth Factor beta1 0
Sodium Bicarbonate 8MDF5V39QO
Creatinine AYI8EX34EU

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

200-208

Subventions

Organisme : CSRD VA
ID : I01 CX001695
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK091437
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK118219
Pays : United States

Informations de copyright

Copyright © 2020 by the American Society of Nephrology.

Références

de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM: Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20: 2075–2084, 2009 19608703
Dubey AK, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada PS: Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: A randomized controlled trial [published online ahead of print July 24, 2018]. Nephrol Dial Transplant. Available at: 10.1093/ndt/gfy214 30053298
Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, Wesson DE: Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 77: 617–623, 2010 20072112
Goraya N, Simoni J, Jo CH, Wesson DE: Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int 86: 1031–1038, 2014 24694986
Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE: Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78: 303–309, 2010 20445497
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150, 2013
Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M’rad MB, Jacquot C, Houillier P, Stengel B, Fouqueray B; NephroTest Study Group: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20: 164–171, 2009 19005010
Raphael KL, Zhang Y, Ying J, Greene T: Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease. Nephrology (Carlton) 19: 648–654, 2014 25066359
Nath KA, Hostetter MK, Hostetter TH: Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 76: 667–675, 1985 2993363
Raphael KL, Gilligan S, Hostetter TH, Greene T, Beddhu S: Association between urine ammonium and urine TGF- β 1 in CKD. Clin J Am Soc Nephrol 13: 223–230, 2018 29146699
Goraya N, Simoni J, Jo CH, Wesson DE: A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol 8: 371–381, 2013 23393104
Goraya N, Simoni J, Jo C, Wesson DE: Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int 81: 86–93, 2012 21881553
Welbourne T, Weber M, Bank N: The effect of glutamine administration on urinary ammonium excretion in normal subjects and patients with renal disease. J Clin Invest 51: 1852–1860, 1972 4555786
Goodman AD, Fuisz RE, Cahill GF Jr: Renal gluconeogenesis in acidosis, alkalosis, and potassium deficiency: Its possible role in regulation of renal ammonia production. J Clin Invest 45: 612–619, 1966 5937032
Eid A, Bodin S, Ferrier B, Delage H, Boghossian M, Martin M, Baverel G, Conjard A: Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats. J Am Soc Nephrol 17: 398–405, 2006 16396963
Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J: Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 102: 619–624, 1998 9691098
Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4: 337–344, 2009 19176795
Hosohata K, Ando H, Takeshita Y, Misu H, Takamura T, Kaneko S, Fujimura A: Urinary Kim-1 is a sensitive biomarker for the early stage of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Diab Vasc Dis Res 11: 243–250, 2014 24821754
Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, Bonventre JV, Krolewski AS: Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int 93: 1198–1206, 2018 29398132
Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D, Sarnak M, Shlipak MG: Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 60: 904–911, 2012 22749388
Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B: Quantification of lean bodyweight. Clin Pharmacokinet 44: 1051–1065, 2005 16176118
Yu L, Border WA, Huang Y, Noble NA: TGF-beta isoforms in renal fibrogenesis. Kidney Int 64: 844–856, 2003 12911534
Chen S, Hong SW, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh FN: The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren Fail 23: 471–481, 2001 11499562
Chen S, Jim B, Ziyadeh FN: Diabetic nephropathy and transforming growth factor-beta: Transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 23: 532–543, 2003 14631561
Dronavalli S, Duka I, Bakris GL: The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4: 444–452, 2008 18607402
Hills CE, Squires PE: TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 31: 68–74, 2010 19887790
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009 19414839
Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ: Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 21: 683–689, 2006 16330466
Tolins JP, Hostetter MK, Hostetter TH: Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest 79: 1447–1458, 1987 3553240
Vallet M, Metzger M, Haymann JP, Flamant M, Gauci C, Thervet E, Boffa JJ, Vrtovsnik F, Froissart M, Stengel B, Houillier P; NephroTest Cohort Study group: Urinary ammonia and long-term outcomes in chronic kidney disease. Kidney Int 88: 137–145, 2015 25760321
Wesson DE, Dolson GM: Endothelin-1 increases rat distal tubule acidification in vivo. Am J Physiol 273: F586–F594, 1997 9362336
Wesson DE, Jo CH, Simoni J: Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR. Nephrol Dial Transplant 30: 762–770, 2015 25527741
Wesson DE, Simoni J: Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int 78: 1128–1135, 2010 20861823

Auteurs

Kalani L Raphael (KL)

Medicine Section, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; and.
Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.

Tom Greene (T)

Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.

Guo Wei (G)

Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.

Tristin Bullshoe (T)

Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.

Kunani Tuttle (K)

Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.

Alfred K Cheung (AK)

Medicine Section, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; and.
Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.

Srinivasan Beddhu (S)

Medicine Section, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; and.
Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH